Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis
Abstract
Review question / Objective: To evaluate the relationship between antidiabetic medications and the risk of prostate cancer among patients with diabetes by performing a systematic review and meta-analysis.Condition being studied: Multiple epidemiological studies and meta-analyses suggested that diabetes was associated with a decreased risk of prostate cancer.A recent study has suspected that the protective effects of prostate cancer may not be only related to diabetes.Instead, the use of a n t i d i a b e t i c m e d i c a t i o n s , s u c h a s m e t f o r m i n , thiazolidinediones, sulfonylureas, insulin, incretin-based therapies and sodium-glucose cotransporter 2 inhibitors may also modify the incidence of prostate cancer.However, the existing studies showed inconsistent results.Additionally, there is no available study that provides a simultaneous and comprehensive assessment of the impacts of all conventional antidiabetic medications on risk modification of prostate cancer.INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 30 June 2020 and was last u p d a t e d o n 3 0 J u n e 2 0 2 0 ( r e g i s t r a t i o n n u m b e r INPLASY202060113).
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.